<DOC>
	<DOCNO>NCT00580606</DOCNO>
	<brief_summary>The purpose study evaluate safety immune response daily sublingual ( tongue ) immunotherapy ( SLIT ) peanut extract adult child peanut allergy .</brief_summary>
	<brief_title>A Randomized , Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial</brief_title>
	<detailed_description>Peanut allergy common ailment United States . Research suggest prevalence peanut allergy United States double last 5 year . Currently , effective treatment peanut allergy peanut-free diet quick access self-injectable epinephrine event peanut exposure . The sublingual route potential method administer immunotherapy treatment food allergy . The intent study induce desensitization eventually tolerance peanut protein evaluate safety immunologic effect daily sublingual immunotherapy ( SLIT ) individual peanut allergy . The trial enroll 40 participant . After first 10 participant age 18 40 enrol , safety information review . If safety concern , study continue enroll remain participant age 12 40 . This clinical trial last 172 216 week . Participants randomly assign receive peanut SLIT placebo SLIT . All participant entry oral food challenge ( OFC ) . The treatment group receive gradual dosing escalation peanut SLIT maintenance therapy 44-week period , follow another OFC . Following OFC , participant unblinded , placebo group receive peanut SLIT escalate high maximum dose first treatment group . Maintenance therapy continue group 2 year . Study visit occur every 2 week dose escalation peanut SLIT , follow visit gradually space maintenance every 12 week . At select visit , physical examination , skin prick test , blood urine collection , atopic dermatitis asthma evaluation occur . Approximately 6 OFCs administer participant throughout course study . Additionally , 10 participant enrol control participant receive study therapy blood drawn 3 visit throughout course trial .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Food Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<mesh_term>Hypersensitivity , Immediate</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<criteria>Physiciandiagnosed peanut allergy OR convince clinical history peanut allergy Reacts cumulative dose 2,000 mg less peanut powder Positive peanut allergy skin prick test OR detectable serum peanutspecific IgE level Willing use acceptable method contraception duration study Ability perform spirometry maneuver accordance American Thoracic Society guideline History severe anaphylaxis peanut Currently participate study use new investigational new drug Participation interventional study treatment food allergy 12 month prior study entry Allergic placebo ingredient ( glycerin oat flour ) OR react dose placebo study entry oral food challenge ( OFC ) Currently buildup phase allergy immunotherapy Poor control atopic dermatitis Moderate severe asthma despite therapy Current treatment great medium daily dos inhale corticosteroid Use steroid medication Use omalizumab nontraditional form allergen immunomodulatory therapy ( include corticosteroid ) biologic therapy 12 month prior study entry Use beta blocker , angiotensinconverting enzyme inhibitor , angiotensinreceptor blocker , calcium channel blocker Inability discontinue antihistamine skin test OFCs History ischemic cardiovascular disease History alcohol drug abuse Other significant medical condition , opinion investigator , prevent participation study Previous intubation due allergy asthma Uncontrolled high blood pressure Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Food Allergy</keyword>
	<keyword>Peanut Allergy</keyword>
	<keyword>Sublingual Immunotherapy</keyword>
</DOC>